ERBB2 and breast cancer: Similarly, in the adjuvant setting, a single pilot experience evaluated the feasibility of the combination of eribulin with capecitabine (days 1–14 of a 21-days cycle) in HR-positive HER2-negative, stage I–II early BC, with preliminary interesting results (Smith et al., 2016).